Feasibility study for marker-based VMAT plan optimization toward tumor tracking.
VMAT
constraints
fiducial marker
plan optimization
tumor tracking
Journal
Journal of applied clinical medical physics
ISSN: 1526-9914
Titre abrégé: J Appl Clin Med Phys
Pays: United States
ID NLM: 101089176
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
02
07
2019
revised:
23
03
2020
accepted:
07
04
2020
pubmed:
12
6
2020
medline:
22
6
2021
entrez:
12
6
2020
Statut:
ppublish
Résumé
This work investigates the incorporation of fiducial marker-based visibility parameters into the optimization of volumetric modulated arc therapy (VMAT) plans. We propose that via this incorporation, one may produce treatment plans that aid real-time tumor tracking approaches employing exit imaging of the therapeutic beam (e.g., via EPID), in addition to satisfying purely dosimetric requirements. We investigated the feasibility of this approach for a thorax and prostate site using optimization software (MonArc). For a thorax phantom and a lung patient, three fiducial markers were inserted around the tumor and VMAT plans were created with two partial arcs and prescription dose of 48 Gy (4 fractions). For a prostate patient with three markers in the prostate organ, a VMAT plan was created with two partial arcs and prescription dose 72.8 Gy (28 fractions). We modified MonArc to include marker-based visibility constraints ("hard"and "soft"). A hard constraint (HC) imposes full visibility for all markers, while a soft constraint (SC) penalizes visibility for specific markers in the beams-eye-view. Dose distributions from constrained plans (HC and SC) were compared to the reference nonconstrained (NC) plan using metrics including conformity index (CI), homogeneity index (HI), gradient measure (GM), and dose to 95% of planning target volume (PTV) and organs at risk (OARs). The NC plan produced the best target conformity and the least doses to the OARs for the entire dataset, followed by the SC and HC plans. Using SC plans provided acceptable dosimetric tolerances for both the target and OARs. However, OAR doses may be increased or decreased based on the constrained marker location and number of trackable markers. In conclusion, we demonstrate that visibility constraints can be incorporated into the optimization together with dosimetric objectives to produce treatment plans satisfying both objectives. This approach should ensure greater clinical success when applying real-time tracking algorithms, using VMAT delivery.
Identifiants
pubmed: 32525615
doi: 10.1002/acm2.12892
pmc: PMC7386299
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
84-99Informations de copyright
© 2020 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, Inc. on behalf of American Association of Physicists in Medicine.
Références
Phys Med Biol. 2013 Feb 21;58(4):749-70
pubmed: 23324560
Radiat Oncol J. 2012 Mar;30(1):27-35
pubmed: 23120741
Med Phys. 2006 Oct;33(10):3874-900
pubmed: 17089851
Med Phys. 2008 Jan;35(1):310-7
pubmed: 18293586
Med Phys. 2010 Nov;37(11):5627-33
pubmed: 21158274
Phys Med Biol. 2005 Sep 7;50(17):4021-33
pubmed: 16177527
Med Phys. 2011 May;38(5):2698-707
pubmed: 21776806
Med Phys. 2013 Mar;40(3):031708
pubmed: 23464303
Cancer Radiother. 2006 Sep;10(5):269-82
pubmed: 16875860
Med Phys. 2009 Jun;36(6):2215-21
pubmed: 19610310
Semin Radiat Oncol. 1999 Jan;9(1):20-34
pubmed: 10196396
Med Phys. 2008 May;35(5):2050-61
pubmed: 18561681
Med Phys. 2004 Dec;31(12):3492-9
pubmed: 15651632
Med Phys. 2012 Nov;39(11):6957-67
pubmed: 23127089
Med Phys. 2011 Jul;38(7):4205-14
pubmed: 21859022
Med Phys. 2002 Jun;29(6):1007-18
pubmed: 12094970
Phys Med Biol. 2012 Dec 7;57(23):R161-91
pubmed: 23165229
Phys Med Biol. 2004 Feb 7;49(3):425-40
pubmed: 15012011
Med Phys. 2010 Aug;37(8):4078-101
pubmed: 20879569